Consensus for HER2 alterations testing in non-small-cell lung cancer
Shengxiang Ren, Jiong Wang, Jianming Ying et al. · ESMO Open · 2022
Human epidermal growth factor receptor 2 (HER2) is a transmembrane glycoprotein receptor with intracellular tyrosine kinase activity. Its alterations, including mutation, amplification and overexpression, could result in oncogenic potential and have been detected in many cancers such as non-small-cell lung cancer (NSCLC). Such alterations are, in general, considered markers of poor prognosis. Anti-HER2 antibody-drug conjugates, e.g. trastuzumab deruxtecan (T-DXd, DS-8201) and disitamab vedotin (RC48), were recently approved for HER2-positive breast and gastric cancers. Meanwhile, several HER2-targeted drugs, such as T-DXd, neratinib, afatinib, poziotinib and pyrotinib, have been evaluated in patients with advanced NSCLC, with several of them demonstrating clinical benefit. Therefore, identifying HER2 alterations is pivotal for NSCLC patients to benefit from these targeted therapies. Recent guidelines on HER2 testing were developed for breast and gastric cancer, however, and have not been fully established for NSCLC. The expert group here reached a consensus on HER2 alteration testing in NSCLC with the focus on clinicopathologic characteristics, therapies, detection methods and diagnostic criteria for HER2-altered NSCLC patients. We hope this consensus could improve the clinical management of NSCLC patients with HER2 alterations.
Cited by 119 works. doi:10.1016/j.esmoop.2022.100395 Open-access PDF
Authors
- Shengxiang Ren
- Jiong Wang
- Jianming Ying
- Tetsuya Mitsudomi
- Daniel Lee
- Zengwu Wang
- Philip C. Mack
- Ying Cheng
- Jianchun Duan
- Yun Fan
- Baohui Han
- Zhouguang Hui
- Aichen Liu
- Jing Liu
- You Lü
- Z. Ma
- Meiqi Shi
- Yongqian Shu
- Qibin Song
References
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis
- Intragenic ERBB2 kinase mutations in tumours
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
- Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas